Video

CSCC: Escalating Therapy for High-risk Patients

Author(s):

Nikhil Kushalani, MD,Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Related Videos
Matthew P. Deek, MD
Peter Forsyth, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Richard Kim, MD, Moffitt Cancer Center
Tiago Biachi, MD, PhD
Related Content
Cancer / Image credit: Cornflakesei – stock.adobe.com
December 2nd 2024

Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Douglas B. Johnson, MD, MSCI
November 22nd 2024

Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction

Blessy Mathew Jacob, MD; Ana Van Der Wall, MD; Vance M. Wright-Browne, MD
February 8th 2024

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors